Valproic acid (Depakene). A new anticonvulsant agent
- 10 November 1978
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 240 (20) , 2190-2192
- https://doi.org/10.1001/jama.240.20.2190
Abstract
Valproic acid, a new anticonvulsant, is most effective in absence seizures (simple and complex), but it has produced improvement in tonicclonic seizures, mixed absence with tonic-clonic seizures, and myoclonic epilepsy. It is useful alone or as an adjunct to other anticonvulsants and may allow the dosage of the latter to be reduced. Some patients who are refractory to other anticonvulsants may respond to valproic acid. Adverse reactions occur in about 20% of patients. Gastrointestinal disturbances and drowsiness (usually noted when valproic acid is given with other anticonvulsants) are the most common reactions; hair loss is observed less frequently. Untoward effects are usually transient and do not require discontinuation of use of the drug. (JAMA 240:2190-2192, 1978)This publication has 2 references indexed in Scilit:
- Valproate Sodium: A Controlled Clinical Trial Including Monitoring of Drug LevelsEpilepsia, 1977
- Treatment of Generalized Epilepsies of Childhood and Adolescence with Sodium Valproate (‘Epilim’)Developmental Medicine and Child Neurology, 1977